European countries in the race to attract successful biopharma investment: Winners and laggers
| Autor: | Isidre March-Chorda, Rosa M. Yagüe-Perales |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Pharmacology Drug Industry Research COVID-19 New Ventures Venture capital Investment (macroeconomics) Europe 03 medical and health sciences Race (biology) 030104 developmental biology 0302 clinical medicine Market economy Drug Development 030220 oncology & carcinogenesis Drug Discovery Position (finance) Business Investments Lagging Pandemics Foundations |
| Zdroj: | Drug Discovery Today. 26:2209-2213 |
| ISSN: | 1359-6446 |
| DOI: | 10.1016/j.drudis.2021.04.001 |
| Popis: | The post-coronavirus era will open myriad opportunities for the biopharma industry. However, the extent to which each country will take advantage of this promising new scenario will largely depend on its position in a few key areas. Here, we offer an overview of the European countries that are winning and those that are lagging behind in the race to attract the greatest investment in this industry and to attain the highest rate of successful new ventures. Our results highlight the vital importance of a sound, active funding base, especially in terms of venture capital. Our findings also suggests that general scientific foundations are not enough to secure an advantage in new venture formation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect